News

With a goal of finding new digital technologies and artificial intelligence (AI) solutions for patients with rare genetic disorders like hereditary angioedema (HAE), and for inflammatory bowel diseases, Takeda Canada has introduced an innovation challenge. Specifically, Takeda Canada is seeking new and breakthrough solutions in early diagnosis, as…

A new mutation in the SERPING1 gene linked to hereditary angioedema (HAE) type 1 was identified in three of five members of a Spanish family. Results were published in a letter to the editor of the journal Pediatric Allergy and Immunology titled “Hereditary angioedema caused by a novel intronic variant of SERPING1.” HAE is a form of…

People with hereditary angioedema (HAE) commonly have histories of cancer, which raises the possibility that it might predispose a person to develop cancer. These findings were reported in the study “Malignancy and immune disorders in patients with hereditary angioedema,” published in the journal Allergy, Asthma…

Excess blood levels of uric acid — a normal body waste product — and Hashimoto’s disease, an autoimmune condition, may increase the risk of angioedema without hives for older adults, according to a study in Poland. Further studies are needed to confirm these findings and better understand the factors…

Pharming Group and Sanofi have renewed an agreement for the manufacturing of Ruconest (conestat alfa), Pharming’s approved treatment for swelling attacks in people with hereditary angioedema (HAE). The two companies have been working together for more than a decade, and now have agreed to extend the collaboration…

Swelling attacks affecting the airway usually occur in hereditary angioedema patients between the ages of 20 and 30 — and are more frequent among smokers, a study shows. However, the frequency of attacks was higher in people with acquired angioedema, a type of the chronic disorder in which…

The National Organization for Rare Disorders (NORD) asks Americans to plan ahead to participate in the Light Up for Rare campaign to raise awareness of rare diseases. NORD is the U.S. sponsor for Rare Disease Day on Feb. 28. The annual awareness day spotlights approximately 7,000…

The first participant has been dosed in a Phase 1/2 clinical trial that is testing Intellia Therapeutics’ gene-editing therapy, NTLA-2002, in people with hereditary angioedema (HAE). “With the progress of our first-in-human clinical study evaluating NTLA-2002 for people living with HAE, we look forward to beginning clinical testing as…

Switching from under-the-skin injections to oral pills of Orladeyo (berotralstat), a preventive treatment, can be done without the need to taper prior therapy or go through complex regimens, according to a case study of a patient and her mother, both of whom have hereditary angioedema (HAE). The report,…

Over a third of hereditary angioedema patients continue to experience an unpredictable rate of annual attacks, including those on long-term preventive therapy, a retrospective analysis shows. These findings highlight the variability of the disease and support the need for constant vigilance by patients and their doctors. The study, “…